BridgeMD
New treatment option for Indolent B-Cell Non-Hodgkin Lymphoma
Official title Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
ClinicalTrials.gov ID: NCT06461182
What this study is testing
What is Ga-68-CXCR4?
Ga-68-CXCR4 is an investigational medicine, being studied as a potential treatment for indolent b-cell non-hodgkin lymphoma.
Also referred to as PET/CT.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 100
You may be able to join if
- The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma...
- Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up...
- Able to lie flat for at least 30 minutes.
- Signing the subject consent form.
- ECOG grade 0-2.
You likely can't join if
- Pregnant woman
- Severe renal impairment (eGRF\< 30ml/min)
- Known or suspected allergy to radiopharmaceuticals
- Concurrent or previous diagnosis of malignancies other than lymphoma
- Inability to undergo the necessary PET scan procedure
- Refusal or unwillingness to sign the informed consent form
See the full eligibility criteria
- The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma.
- Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group.
- Able to lie flat for at least 30 minutes.
- Signing the subject consent form.
- ECOG grade 0-2.
- The timing of F-18-FDG usage in this trial follows the "Lymphoma Treatment Principles" of our institution.
- Pregnant woman
- Severe renal impairment (eGRF\< 30ml/min)
- Known or suspected allergy to radiopharmaceuticals
- Concurrent or previous diagnosis of malignancies other than lymphoma
- Inability to undergo the necessary PET scan procedure
- Refusal or unwillingness to sign the informed consent form
- Severe medical conditions (severe disabilities, mental disorders)
The study team makes the final eligibility decision.
Where it's taking place
- Taipei, Beitou, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taipei, Beitou, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.